DOCSLIB.ORG

Evolution in the Therapeutics of Respiratory Viral Infections

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Evolution in the Therapeutics of Respiratory Viral Infections EVOLUTION IN THE THERAPEUTICS OF RESPIRATORY© by VIRAL author INFECTIONS ESCMID OnlineS. Tsiodras, Lecture MD, PhD Library Asst Professor of Internal Medicine & Infectious Diseases University of Athens Medical School Respiratory viral infections © by author ESCMID Online Lecture Library Lancet 2011; 377: 1264–75 Lower RTIs - Associations Bronchiolitis RSV, hMPV, PIV, adeno Wheezing/Asthma RSV, hMPV, rhinovirus Croup PIV Pneumonia © byflu, author PIV, adeno, RSV ESCMID Pneumonitis Online Tx RSV, Lecture PIV, flu, LibraryhMPV, adeno Clinical Infectious Diseases 2011;52(S4):S284–S289 VIRAL PNEUMONIAS Most frequent causes – Influenza – Respiratory syncytial virus (RSV) – Parainfluenza – Human metapneumovirus – Human bocavirus – Rhinoviruses © by author ESCMID– Coronaviruses Online Lecture Library – Adenoviruses – Echo, Coxsackie Lancet 2011; 377: 1264–75 CAP - Viruses vs. Bacteria © by author ESCMID Online Lecture Library Lancet 2011; 377: 1264–75 CAP - Viruses vs. Bacteria © by author ESCMID Online Lecture Library Lancet 2011; 377: 1264–75 SPECIFIC PATHOGENS © by author ESCMID Online Lecture Library Influenza is here every year !!! © by author ESCMID Online Lecture Library Antiviral Therapies for Influenza Neuraminidase (NA) NA Inhibitors • Oseltamivir • Zanamivir Matrix protein (M2 ) © by author M2 Inhibitors ESCMID Online Lecture• Amantadine Library • Rimantadine © by author ESCMID Online Lecture Library Influenza & Antivirals Outcome AM/RM ZNV OSEL symptoms YES YES YES Prevent complications ? YES YES Abx use ? 28% 24-40% Hospitalization © by author? ? ~50% Treat complications ? ? ? ESCMID Online Lecture Library transmission ? (30%) ? ? ?= No placebo-controlled study or not reported © by author ESCMID Online Lecture Library CID 2010:50 (1 April) • Ling et al © by author ESCMID Online Lecture Library CID 2010:50 (1 March) • © by author ESCMID Online Lecture Library Influenza in the Community Mild forms – Fever, coryza – General sxs headache, malaise© by, myalgia author/arthralgia & GI Sxs NO evidence of complications –ESCMID Online Lecture Library Influenza in the Community e.g. >65yrs, chronic dz, pregnancy, BMI>40 e.g. ChemoRx, BMT, SOT, HIV w CD4< 200 © by author ESCMID Online Lecture Library Influenza in the Community Severe forms - Complications – Requiring hospital admission – Sxs & signs of LRTI hypoxemia, dyspnea, lung infiltrate on CxR © by author – CNS involvement ESCMID Online Lecture Library – exacerbation of underlying medical condition Influenza in the Community e.g. ChemoRx, BMT, SOT, HIV w CD4< 200 © by author ESCMID Online Lecture Library MAIN POINTS FOR INFLUENZA Rx Mild uncomplicated influenza Rx only population at risk for complications Complicated© influenza by author or worsening ESCMID OnlineRx Lecture all Library © by author ESCMID Online Lecture Library Adverse effects Oseltamivir – GI tract nausea vomit – Take w food ? Encephalitis © by author AllergicESCMID rash Online Lecture Library ? Neuro-psych effects © by author ESCMID Online Lecture Library Relenza® (zanamivir for inhalation) Rotadisk® and Diskhaler® Mouthpiece Piercing Needle © by author Rotadisk ESCMIDCover Online LectureInhalatio Library n Powder © by author ESCMID Online Lecture Library CID 2010:50 (1 March) • Oseltamivir Drug - Drug interactions Clopidogrel – Oseltamivir hydrolysis to active metabolite © by author ESCMID Online JLecture Pharmac Exp LibraryTher 2006 © by author ESCMID Online Lecture Library © by author ESCMID Online Lecture Library © by author ESCMID Online Lecture Library Australian influenza report 2011 Emerging Infectious Diseases, Vol. 17, 2011;653-660 • 594 isolates – 238 Interntl 84 pH1N1, 76 A(H3N2), 78 B – 356 USA © by30 authorpH1N1, 158 A(H3N2), 168 B ESCMID Online Lecture Library • All A (H3N2) susceptible to NAIs • 1 pH1N1 US oselt R, zana S (H275Y) © by author • < 1% of 3000 tested viruses were R to NAIs •ESCMIDAll R to adamantanes Online Lecture Library • 1374 viruses tested – 11 A(H1N1)pdm09© byH275Y author mutation oselt R – 1 A(H1N1)pdm09 Y155H mutation oselt/zan R –ESCMID1 A(H3N2)pdm09 Online D151N Lecture mutation Libraryoselt/zan R – 1 B virus I221T mutation oselt R /zan S – All A (H3N2), A(H1N1)pdm09 tested adamantane R Neuraminidase Inhibitor resistance © by author ESCMID Online Lecture Library © by author ESCMID Online Lecture Library © by author ESCMID Online Lecture Library Other antivirals for influenza Research level or compassionate use – iv zanamivir, aqueous solution zanamivir – iv oseltamivir – iv peramivir – inh Laninamivir – iv ribavirin © by author ESCMID– Monoclonal OnlineAb Lecture Library – DAS181, favipiravir, nitazoxanide and AVI-7100 Peramivir is the Most Potent in vitro against H1N1 among those studied © by author ESCMID Online Lecture Library © by author ESCMID Online Lecture Library © by author ESCMID Online Lecture Library H7N9 INFLUENZA – China 2013 © by author ESCMID Online Lecture Library • 108/111 pts Rx – received NAIs – oseltamivir or peramivir© by author • Median t 7 days !!! –ESCMID9.9% within 48 Online hrs Lecture Library • Abxs 71.2% © by author ESCMID OnlineHuman Lecture monoclonal antibody Library CR8020 w broad neutralizing activity against most group 2 viruses, including H3N2 and H7N7 Science, 2011: 843-850 © by author ESCMID Online Lecture Library Science, 2011: 843-850 © by author ESCMID Online Lecture Library Science, 2011: 843-850 Figure 8. The pockets on the predicted structures explored by AutoDock based on a subunit: © by author ESCMID Online Lecture Library Cui W, Wang K, Ruan J, Qi Z, et al. (2012) The Molecular Mechanism of Action of the CR6261-Azithromycin Combination Found through Computational Analysis. PLoS ONE 7(5): e37790. doi:10.1371/journal.pone.0037790 http://www.plosone.org/article/info:doi/10.1371/journal.pone.0037790 Rhinovirus Therapeutics • Antivirals – Pleconaril • 3C protease inhibitors (e.g. nasal spray of ruprintrivir) – AAC 2003; 47(12): 3907-16. • Interferon alpha-2b for prophylaxis – N Engl J Med 1986; 314:71. • Soluble ICAM-1 (Tremacamra© by author) – JAMA 1999; 281:1797 • ESCMIDVLDL and LDL receptorOnline fragments Lecture Library – J Virol 1998; 72:10246 Rhinoviruses © by author ESCMID Online Lecture Library Thibaut HJ et al. Biochemical pharmacology. 2012;83(2):185-92 Rhinoviruses © by author ESCMID Online Lecture Library Rhinoviruses © by author ESCMIDRESULTS HAVE Online NOT BEEN LectureREPORTED TO DATE Library !!! ??? Enterovirus Wide range of clinical manifestations Several serotypes respiratory dz Pharyngitis common © by author ESCMID Online Lecture Library Enterovirus • Several targets for inhibition of viral replication – viral 3C protease© by author ESCMID– the putative Online2C helicase Lecture Library – the 3D RNA-dependent RNA polymerase • Inhibitors against host cell factors, IVIG Enteroviruses © by author ESCMID Online Lecture Library Thibaut HJ et al. Biochemical pharmacology. 2012;83(2):185-92 Parainfluenza virus • Croup (types 1, 2), laryngitis • Pneumonia (type 3) in children 6 m – 3 yrs • Pneumonia in immunocompromised – BMT units (type© 3 )by author • Rx: ribavirin, ? NAIs, recombinant sialidase ESCMID Online Lecture Library fusion protein (DAS 181) The Journal of infectious diseases 2010; 202(2): 234-41. Transplant infectious disease 2012; 14(4): 427-33. RSV Alveolar obstruction Syncytia formation Inflammatory cell infiltrate © by author Sloughing of respiratory ESCMID Online Lecture epitheliumLibrary Prevention • Palivizumab = Synagis – RSV-F protein-specif. humanized monoclonal Ab • Impairs fusion & resp epithelium entry, NO role in Rx – Children < 2 yrs & risk • Prematurity, bronchopulmonary© by author dysplasia, neuromuscular dz, congenital heart disease, CLD, immunodeficiency – ESCMIDChildren w recurrent Online wheezing Lecture that had Library RSV infxn – cost Motavizumab © by author ESCMID Online Lecture Library Pediatr Res 70: 186–191, 2011 RSV Rx Supportive, Abx if mixed bacterial infection RSV IG Ribavirin – NOT as routine© Rx by author ESCMID– LRTI, severe Online dz Lecture Library RSV Rx – novel agents Monoclonal Ab against G protein . Experimental data, mice Small molecules . BMS-433771, TMC353121, JNJ-2408068, VP14637 . NMSO3, YM-53404,© byRSV604 author siESCMID RNAs Online Lecture Library Lundin et al., 2010; Haynes LM JID 2009; Miao C J Gen Virol. 2009; Collins P et al. J. Immunol. 2009;183 (10), 6338–6345, PLoS One. 2012;7(12):e51485. © by author ESCMID Online Lecture Library PNAS 2010 ; 107;8800-05 © by author ESCMID Online Lecture Library © by author ESCMID Online Lecture Library Human Metapneumovirus Epi & clinical picture similar to RSV Max incidence between 4-6 months of age Frequent coinfection w RSV © by author Frequently mild or asymptomatic infection ESCMID Online Lecture Library J. Williams et al. NEJM 2004;350:5 Xepapadaki P et al. J Clin Virol 2004 Jul;30(3):267-70 HMPV in immunosupression © by author ESCMID Online Lecture Library Transpl Infect Dis 2011: 13: 324–328 Human Metapneumovirus Rx Ribavirin iv vs. oral vs. nebulized (SPAG) Ribavirin + IVIG Monoclonal Abs siRNA ? © by author ESCMID Online Lecture Library Transpl Infect Dis 2011: 13: 324–328 Virology Journal 2012, 9:105 ADENOVIRUS 51 serotypes – Pharyngo-conjunctivitis / association w pools – Immunocompromised, BMT (60 % mortality) – Military recruits - CAP 10-20% © by author Rx: Ribavirin ± IVIG, Cidofovir, Vidarabine ESCMID Online Lecture Library Transplantation 2007; 13(1): 74-81 Bone Marrow Transplant. 2013 Mar 18 SARS Ribavirin NA Protease inhibitors – Lopinavir/ritonavir – Nelfinavir
Load more

Recommended publications
  • Antiviral Agents Active Against Influenza a Viruses
    REVIEWS Antiviral agents active against influenza A viruses Erik De Clercq Abstract | The recent outbreaks of avian influenza A (H5N1) virus, its expanding geographic distribution and its ability to transfer to humans and cause severe infection have raised serious concerns about the measures available to control an avian or human pandemic of influenza A. In anticipation of such a pandemic, several preventive and therapeutic strategies have been proposed, including the stockpiling of antiviral drugs, in particular the neuraminidase inhibitors oseltamivir (Tamiflu; Roche) and zanamivir (Relenza; GlaxoSmithKline). This article reviews agents that have been shown to have activity against influenza A viruses and discusses their therapeutic potential, and also describes emerging strategies for targeting these viruses. HXNY In the face of the persistent threat of human influenza A into the interior of the virus particles (virions) within In the naming system for (H3N2, H1N1) and B infections, the outbreaks of avian endosomes, a process that is needed for the uncoating virus strains, H refers to influenza (H5N1) in Southeast Asia, and the potential of to occur. The H+ ions are imported through the M2 haemagglutinin and N a new human or avian influenza A variant to unleash a (matrix 2) channels10; the transmembrane domain of to neuraminidase. pandemic, there is much concern about the shortage in the M2 protein, with the amino-acid residues facing both the number and supply of effective anti-influenza- the ion-conducting pore, is shown in FIG. 3a (REF. 11). virus agents1–4. There are, in principle, two mechanisms Amantadine has been postulated to block the interior by which pandemic influenza could originate: first, by channel within the tetrameric M2 helix bundle12.
    [Show full text]
  • Summary of Neuraminidase Amino Acid Substitutions Associated with Reduced Inhibition by Neuraminidase Inhibitors
    Summary of neuraminidase amino acid substitutions associated with reduced inhibition by neuraminidase inhibitors. Susceptibility assessed by NA inhibition assays Source of Type/subtype Amino acid N2 b (IC50 fold change vs wild type [NAI susceptible virus]) viruses/ References Comments substitutiona numberinga Oseltamivir Zanamivir Peramivir Laninamivir selection withc A(H1N1)pdm09 I117R 117 NI (1) RI (10) ? ?d Sur (1) E119A 119 NI/RI (8-17) RI (58-90) NI/RI (7-12) RI (82) RG (2, 3) E119D 119 RI (25-23) HRI (583-827) HRI (104-286) HRI (702) Clin/Zan; RG (3, 4) E119G 119 NI (1-7) HRI (113-1306) RI/HRI (51-167) HRI (327) RG; Clin/Zan (3, 5, 6) E119V 119 RI (60) HRI (571) RI (25) ? RG (5) Q136K/Q 136 NI (1) RI (20) ? ? Sur (1) Q136K 136 NI (1) HRI (86-749) HRI (143) RI (42-45) Sur; RG; in vitro (2, 7, 8) Q136R was host Q136R 136 NI (1) HRI (200) HRI (234) RI (33) Sur (9) cell selected D151D/E 151 NI (3) RI (19) RI (14) NI (5) Sur (9) D151N/D 151 RI (22) RI (21) NI (3) NI (3) Sur (1) R152K 152 RI(18) NI(4) NI(4) ? RG (3, 6) D199E 198 RI (16) NI (7) ? ? Sur (10) D199G 198 RI (17) NI (6) NI (2) NI (2) Sur; in vitro; RG (2, 5) I223K 222 RI (12–39) NI (5–6) NI (1–4) NI (4) Sur; RG (10-12) Clin/No; I223R 222 RI (13–45) NI/RI (8–12) NI (5) NI (2) (10, 12-15) Clin/Ose/Zan; RG I223V 222 NI (6) NI (2) NI (2) NI (1) RG (2, 5) I223T 222 NI/RI(9-15) NI(3) NI(2) NI(2) Clin/Sur (2) S247N 246 NI (4–8) NI (2–5) NI (1) ? Sur (16) S247G 246 RI (15) NI (1) NI (1) NI (1) Clin/Sur (10) S247R 246 RI (36-37) RI (51-54) RI/HRI (94-115) RI/HRI (90-122) Clin/No (1)
    [Show full text]
  • Journal Pre-Proof
    Journal Pre-proof Ongoing Clinical Trials for the Management of the COVID-19 Pandemic M.P. Lythgoe, P. Middleton PII: S0165-6147(20)30070-5 DOI: https://doi.org/10.1016/j.tips.2020.03.006 Reference: TIPS 1706 To appear in: Trends in Pharmacological Sciences Please cite this article as: M.P. Lythgoe and P. Middleton, Ongoing Clinical Trials for the Management of the COVID-19 Pandemic, Trends in Pharmacological Sciences (2020), https://doi.org/10.1016/j.tips.2020.03.006 This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. © 2020 Published by Elsevier. Journal Pre-proof Ongoing Clinical Trials for the Management of the COVID-19 Pandemic *MP Lythgoe1 & *P Middleton2 1Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, Du Cane Road, W120HS, London, UK 2 Department of Metabolism, Digestion & Reproduction, Imperial College London, St Marys Hospital, Praed Street, W21NY, London UK *Equal contribution Corresponding Email: [email protected] Key words: Coronavirus, SARS-CoV-2, COVID-19, 2019-nCoV, pandemic ABSTRACT COVID-19 has rapidly developed into a worldwide pandemic causing a significant health and economic burden.
    [Show full text]
  • Influenza Antiviral Medications: Summary for Clinicians
    Influenza Antiviral Medications: Summary for Clinicians The information on this page should be considered current for the 2014-2015 influenza season for clinical practice regarding the use of influenza antiviral medications. This page contains excerpts from Antiviral Agents for the Treatment and Chemoprophylaxis of Influenza - Recommendations of the Advisory Committee on Immunization Practices (ACIP). PDF Version[1 MB, 28 pages] Antiviral medications with activity against influenza viruses are an important adjunct to influenza vaccine in the control of influenza. Influenza antiviral prescription drugs can be used to treat influenza or to prevent influenza. Four licensed prescription influenza antiviral agents are available in the United States. o Two FDA-approved influenza antiviral medications are recommended for use in the United States during the 2014-2015 influenza season: oral oseltamivir (Tamiflu®) and inhaled zanamivir (Relenza®). Oseltamivir and zanamivir are chemically related antiviral medications known as neuraminidase inhibitors that have activity against both influenza A and B viruses. o Amantadine and rimantadine are antiviral drugs in a class of medications known as adamantanes. These medications are active against influenza A viruses, but not influenza B viruses. As in recent past seasons, there continues to be high levels of resistance (>99%) to adamantanes among influenza A (H3N2) and influenza A (H1N1) pdm09 ("2009 H1N1") viruses. Therefore, amantadine and rimantadine are not recommended for antiviral treatment or chemoprophylaxis of currently circulating influenza A viruses. Antiviral resistance to oseltamivir and zanamivir among circulating influenza viruses is currently low, but this can change. Also, antiviral resistance can emerge during or after treatment in some patients (e.g., immunosuppressed).
    [Show full text]
  • In Vitro Activity of Favipiravir and Neuraminidase Inhibitor Combinations Against Oseltamivir-Sensitive and Oseltamivir-Resistant Pandemic Influenza a (H1N1) Virus
    Arch Virol DOI 10.1007/s00705-013-1922-1 ORIGINAL ARTICLE In vitro activity of favipiravir and neuraminidase inhibitor combinations against oseltamivir-sensitive and oseltamivir-resistant pandemic influenza A (H1N1) virus E. Bart Tarbet • Almut H. Vollmer • Brett L. Hurst • Dale L. Barnard • Yousuke Furuta • Donald F. Smee Received: 16 July 2013 / Accepted: 6 November 2013 Ó Springer-Verlag Wien (outside the USA) 2013 Abstract Few anti-influenza drugs are licensed in the favipiravir was combined with the NAIs against the osel- United States for the prevention and therapy of influenza A tamivir-sensitive influenza virus, and an additive effect and B virus infections. This shortage, coupled with contin- against the oseltamivir-resistant virus. Although the clinical uously emerging drug resistance, as detected through a global relevance of these drug combinations remains to be evalu- surveillance network, seriously limits our anti-influenza ated, results obtained from this study support the use of armamentarium. Combination therapy appears to offer sev- combination therapy with favipiravir and NAIs for treatment eral advantages over traditional monotherapy in not only of human influenza virus infections. delaying development of resistance but also potentially enhancing single antiviral activity. In the present study, we evaluated the antiviral drug susceptibilities of fourteen pan- Introduction demic influenza A (H1N1) virus isolates in MDCK cells. In addition, we evaluated favipiravir (T-705), an investigational Influenza is a highly contagious acute viral infection that drug with a broad antiviral spectrum and a unique mode of has afflicted mankind for centuries [1]. It continues to be a action, alone and in dual combination with the neuraminidase substantial source of morbidity and mortality with an inhibitors (NAIs) oseltamivir, peramivir, or zanamivir, enormous financial and socioeconomic impact [2].
    [Show full text]
  • Usage of Antivirals and the Occurrence of Antiviral Resistance in Norway 2018
    REPORT 2019 Usage of Antivirals and the Occurrence of Antiviral Resistance in Norway 2018 RAVN Resistensovervåking av virus i Norge Resistance against Antivirals in Norway Usage of Antivirals and the Occurrence of Antiviral resistance in Norway 2018 RAVN Resistensovervåkning av virus i Norge Resistance against antivirals in Norway 2 Published by the Norwegian Institute of Public Health Division of Infection Control and Environmental Health Department for Infectious Disease registries October 2019 Title: Usage of Antivirals and the Occurrence of Antiviral Resistance in Norway 2018. RAVN Ordering: The report can be downloaded as a pdf at www.fhi.no Graphic design cover: Fete Typer ISBN nr: 978-82-8406-032-3 Emneord (MeSH): Antiviral resistance Any usage of data from this report should include a specific reference to RAVN. Suggested citation: RAVN. Usage of Antivirals and the Occurrence of Antiviral Resistance in Norway 2018. Norwegian Institute of Public Health, Oslo 2019 Resistance against antivirals in Norway • Norwegian Institute of Public Health 3 Table of contents Introduction _________________________________________________________________________ 4 Contributors and participants __________________________________________________________ 5 Sammendrag ________________________________________________________________________ 6 Summary ___________________________________________________________________________ 8 1 Antivirals and development of drug resistance ______________________________________ 10 2 The usage of antivirals in Norway
    [Show full text]
  • Antivirals for COVID-19 Posted May 7, 2020
    COVID-19 CURBSIDE CONSULTS Pavithra Srinivas, PharmD Gretchen Sacha, PharmD Christine Koval, MD Inpatient Pharmacy, Cleveland Clinic Inpatient Pharmacy, Cleveland Clinic Infectious Disease, Respiratory Institute, Cleveland Clinic Antivirals for COVID-19 Posted May 7, 2020 ■ ABSTRACT that antiviral drug development against other RNA Drugs targeting RNA respiratory viruses has resulted respiratory viruses has resulted in very few effective in few effective therapies, highlighting challenges for therapies. This is primarily due to poorly character- antivirals to treat COVID-19. Several antivirals are being ized RNA polymerases and weak clinical activity of investigated for symptomatic COVID-19 but no defi nitive nucleoside analogs (ribavirin for respiratory syncytial data support their clinical use. Remdesivir, with good virus [RSV] and parainfl uenza). For the developed in vitro activity against SARS-CoV2, appeared to result non-nucleoside drugs (neuraminidase inhibitors in favorable outcomes for hospitalized patients in a and adamantanes for infl uenza) clinical challenges compassionate use series with shortened time to recovery include short therapeutic windows, limited effects on and a modest decrease in mortality. Currently, remdesivir the severely ill, and drug resistance. While the fol- is available in phase III clinical trials, the compassionate lowing antivirals are of interest for treating symptom- use program, and eventually through the emergency use atic COVID-19, they may suffer the same challenges. authorization. A randomized controlled trial of lopinavir/ Those drugs with evidence of clinical activity may ritonavir demonstrated no apparent clinical or virologic also warrant investigation as prevention in high risk benefi t and drug-drug interactions and side effects further populations. limit its utility.
    [Show full text]
  • Usage of Antivirals and the Occurrence of Antiviral Resistance in Norway 2017
    RAPPORT 2018 Usage of Antivirals and the Occurrence of Antiviral Resistance in Norway 2017 RAVN Resistensovervåking av virus i Norge Resistance against Antivirals in Norway Usage of Antivirals and the Occurrence of Antiviral Resistance in Norway 2017 RAVN Resistensovervåking av virus i Norge Resistance against Antivirals in Norway 2 Published by Norwegian Institute of Public Health Department for Infectious disease registries 2018 Title: Usage of Antivirals and the Occurrence of Antiviral Resistance in Norway 2017. RAVN Ordering: Electronic copy (pdf): www.fhi.no Cover design: Fete typer ISBN: 978-82-8082-973-3 Emneord (MeSH): Antiviral resistance Any use of data from RAVN 2017 should include specific reference to this report. Suggested citation: RAVN 2017. Usage of antivirals and the Occurrence of Antiviral Resistance in Norway. Norwegian Institute of Public Health, Oslo 2018. Usage of Antivirals and the Occurence of Antivarals Resistance in Norway • Folkehelseinstituttet 3 Innhold Introduction _______________________________________________________________________ 4 Contributors and participants _________________________________________________________ 5 Sammendrag _______________________________________________________________________ 6 Summary __________________________________________________________________________ 8 1 The usage oF antivirals in Norway ____________________________________________________ 10 Influenza virus 11 HIV 11 Hepatitis B virus 13 Hepatitis C virus 14 Human herpesviruses 15 References 16 2 Influenza virus
    [Show full text]
  • SARS-Cov-2: an Update on Potential Antivirals in Light of SARS-Cov Antiviral Drug Discoveries
    Review SARS-CoV-2: An Update on Potential Antivirals in Light of SARS-CoV Antiviral Drug Discoveries Hatem A. Elshabrawy Department of Molecular and Cellular Biology, College of Osteopathic Medicine, Sam Houston State University, Conroe, TX 77304, USA; [email protected] Received: 18 May 2020; Accepted: 17 June 2020; Published: 23 June 2020 Abstract: Coronaviruses (CoVs) are a group of RNA viruses that are associated with different diseases in animals, birds, and humans. Human CoVs (HCoVs) have long been known to be the causative agents of mild respiratory illnesses. However, two HCoVs associated with severe respiratory diseases are Severe Acute Respiratory Syndrome-CoV (SARS-CoV) and Middle East Respiratory Syndrome-CoV (MERS-CoV). Both viruses resulted in hundreds of deaths after spreading to several countries. Most recently, SARS-CoV-2 has emerged as the third HCoV causing severe respiratory distress syndrome and viral pneumonia (known as COVID-19) in patients from Wuhan, China, in December 2019. Soon after its discovery, SARS-CoV-2 spread to all countries, resulting in millions of cases and thousands of deaths. Since the emergence of SARS-CoV, many research groups have dedicated their resources to discovering effective antivirals that can treat such life-threatening infections. The rapid spread and high fatality rate of SARS-CoV-2 necessitate the quick discovery of effective antivirals to control this outbreak. Since SARS-CoV-2 shares 79% sequence identity with SARS-CoV, several anti-SARS-CoV drugs have shown promise in limiting SARS-CoV-2 replication in vitro and in vivo. In this review, we discuss antivirals described for SARS-CoV and provide an update on therapeutic strategies and antivirals against SARS-CoV-2.
    [Show full text]
  • A Computational Approach to Aid Clinicians in Selecting Anti-Viral
    www.nature.com/scientificreports OPEN A computational approach to aid clinicians in selecting anti‑viral drugs for COVID‑19 trials Aanchal Mongia1, Sanjay Kr. Saha2, Emilie Chouzenoux3* & Angshul Majumdar1* The year 2020 witnessed a heavy death toll due to COVID‑19, calling for a global emergency. The continuous ongoing research and clinical trials paved the way for vaccines. But, the vaccine efcacy in the long run is still questionable due to the mutating coronavirus, which makes drug re‑positioning a reasonable alternative. COVID‑19 has hence fast‑paced drug re‑positioning for the treatment of COVID‑19 and its symptoms. This work builds computational models using matrix completion techniques to predict drug‑virus association for drug re‑positioning. The aim is to assist clinicians with a tool for selecting prospective antiviral treatments. Since the virus is known to mutate fast, the tool is likely to help clinicians in selecting the right set of antivirals for the mutated isolate. The main contribution of this work is a manually curated database publicly shared, comprising of existing associations between viruses and their corresponding antivirals. The database gathers similarity information using the chemical structure of drugs and the genomic structure of viruses. Along with this database, we make available a set of state‑of‑the‑art computational drug re‑positioning tools based on matrix completion. The tools are frst analysed on a standard set of experimental protocols for drug target interactions. The best performing ones are applied for the task of re‑positioning antivirals for COVID‑19. These tools select six drugs out of which four are currently under various stages of trial, namely Remdesivir (as a cure), Ribavarin (in combination with others for cure), Umifenovir (as a prophylactic and cure) and Sofosbuvir (as a cure).
    [Show full text]
  • Pharmacological Approaches to the Treatment of COVID-19 Patients
    Journal of Translational Science Research Article ISSN: 2059-268X Pharmacological approaches to the treatment of COVID-19 patients Lawrence C Sowers1,2*, Lucas S Blanton2, Scott C Weaver3,4, Randall J Urban2 and Charles P Mouton5 1Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas 2Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas 3Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas 4World Reference Center for Emerging Viruses and Arboviruses 5Department of Family Medicine, University of Texas Medical Branch, Galveston, Texas Abstract The current COVID-19 pandemic has presented unprecedented challenges to the world community. No effective therapies or vaccines have yet been established. Upon the basis of homologies to similar coronaviruses, several potential drug targets have been identified and are the focus of both laboratory and clinical investigation. The rationale for several of these drug candidates is presented in this review. Emerging clinical data has revealed that severe COVID-19 disease is associated with heightened inflammatory responses and a procoagulant state, suggesting that patient treatment strategies must extend beyond antiviral agents. Effective approaches to the treatment of vulnerable patients with comorbidities will render COVID-19 substantially more manageable. Introduction therapies will be developed. The purpose of this review is to outline a portion of the existing body of scientific information which ultimately In December 2019, a novel virus was reported in Wuhan, China might form the basis for a cure. which caused severe respiratory distress and death in some patients [1,2]. The 2019 virus was identified as a novel coronavirus (CoV) COVID-19, the clinical presentation named SARS-CoV-2 which causes COVID-19.
    [Show full text]
  • Text and Network-Mining for COVID-19 Intervention Studies
    Text and Network-Mining for COVID-19 Intervention Studies Aditya Rao ([email protected]) Saipradeep VG ([email protected]) Thomas Joseph ([email protected]) Sujatha Kotte ([email protected]) Naveen Sivadasan ([email protected]) Rajgopal Srinivasan* ([email protected]) TCS Research and Innovation, Hyderabad-500081, INDIA Abstract Background: The COVID-19 pandemic has led to a massive and collective pursuit by the research community to find effective diagnostics, drugs and vaccines The large and growing body of literature present in MEDLINE and other online resources including various self- archive sites are invaluable for these efforts. MEDLINE has more than 30 million abstracts and an additional corpus related to COVID-19, SARS and MERS has more than 40,000 lit- erature articles, and these numbers are growing. Automated extraction of useful information from literature and automated generation of novel insights is crucial for accelerated discovery of drug/vaccine targets and re-purposing drug candidates. Methods: We applied text-mining on MEDLINE abstracts and the CORD-19 corpus to extract a rich set of pair-wise correlations between various biomedical entities. We built a comprehensive pair-wise entity association network involving 15 different entity types using both text-mined associations as well as novel associations obtained using link prediction. The resulting network, which we call CoNetz, also contains a specialized COVID-19 subnetwork that provides a network view of COVID-19 related literature. Additionally, we developed a set of network exploration utilities and user-friendly network visualization utilities using NetworkX and PyVis. Results: CoNetz consisted of pair-wise associations involving ∼174,000 entities covering 15 different entity types.
    [Show full text]